CGON Relative Valuation - CG Oncology Inc - Alpha Spread
C

CG Oncology Inc
NASDAQ:CGON

Watchlist Manager
CG Oncology Inc
NASDAQ:CGON
Watchlist
Price: 39 USD -0.28% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
CG Oncology Inc?
Write Note

Relative Value

The Relative Value of one CGON stock under the Base Case scenario is 44.81 USD. Compared to the current market price of 39 USD, CG Oncology Inc is Undervalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CGON Relative Value
Base Case
44.81 USD
Undervaluation 13%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
40
vs Industry
2
Median 3Y
3 021
Median 5Y
3 021
Industry
7.8
Forward
2 203.2
vs History
vs Industry
Median 3Y
-25.4
Median 5Y
-25.4
Industry
23.7
Forward
-26.8
vs History
vs Industry
Median 3Y
-30
Median 5Y
-30
Industry
22.3
vs History
vs Industry
Median 3Y
-24.7
Median 5Y
-24.7
Industry
24.8
vs History
40
vs Industry
22
Median 3Y
4.6
Median 5Y
4.6
Industry
2.5
vs History
40
vs Industry
2
Median 3Y
2 341.5
Median 5Y
2 341.5
Industry
7.6
Forward
1 734.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.8
vs History
vs Industry
Median 3Y
-20.2
Median 5Y
-20.2
Industry
4.8
Forward
-19.9
vs History
vs Industry
Median 3Y
-20.2
Median 5Y
-20.2
Industry
4.5
Forward
-19.5
vs History
vs Industry
Median 3Y
-22.9
Median 5Y
-22.9
Industry
6.4
vs History
vs Industry
Median 3Y
-22.9
Median 5Y
-22.9
Industry
4.4
vs History
9
vs Industry
1
Median 3Y
267.2
Median 5Y
267.2
Industry
4.8

Multiples Across Competitors

CGON Competitors Multiples
CG Oncology Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CG Oncology Inc
NASDAQ:CGON
2.6B USD 3 080.3 -25.1 -19.7 -19.7
US
Abbvie Inc
NYSE:ABBV
341.7B USD 6.2 64.5 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
181.2B USD 5.9 57.9 20.2 36.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127.2B USD 9.4 29.4 25.8 28.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120B USD 11.6 -244.9 26 27.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
US
Gilead Sciences Inc
NASDAQ:GILD
104.6B USD 3.8 99.3 9.4 12
AU
CSL Ltd
ASX:CSL
141.9B AUD 6.5 36.6 22.4 27.9
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.1B USD 15 -481 211.7 325.9
P/E Multiple
Earnings Growth
US
C
CG Oncology Inc
NASDAQ:CGON
Average P/E: 57.5
Negative Multiple: -25.1
N/A
US
Abbvie Inc
NYSE:ABBV
64.5
406%
US
Amgen Inc
NASDAQ:AMGN
57.9
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.4
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -244.9
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
AU
CSL Ltd
ASX:CSL
36.6
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -481 N/A
EV/EBITDA Multiple
EBITDA Growth
US
C
CG Oncology Inc
NASDAQ:CGON
Average EV/EBITDA: 47.3
Negative Multiple: -19.7
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.8
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
39%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
211.7
N/A
EV/EBIT Multiple
EBIT Growth
US
C
CG Oncology Inc
NASDAQ:CGON
Average EV/EBIT: 68.9
Negative Multiple: -19.7
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.7
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.6
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.3
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
AU
CSL Ltd
ASX:CSL
27.9
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
325.9
N/A

See Also

Discover More
Back to Top